Cross-Resistance: One Cancer Therapy Can Undermine the Next
Cross-Resistance: One Cancer Therapy Can Undermine the Next
Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.
Cross-Resistance: One Cancer Therapy Can Undermine the Next
Cross-Resistance: One Cancer Therapy Can Undermine the Next

Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.

Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.

cancer immunology
Harnessing Stem Cell–Like T Cells to Better Fight Cancer
Harnessing Stem Cell–Like T Cells to Better Fight Cancer
Daniel E. Speiser and Werner Held | Jul 13, 2020
Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.
Miracle Elixirs
Miracle Elixirs
Bob Grant | Apr 1, 2019
A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
Kerry Grens | Apr 1, 2019
The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.
Making CAR T-Cell Therapy Safer
Making CAR T-Cell Therapy Safer
Catherine Offord | Apr 1, 2017
Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.
Neoantigens Enable Personalized Cancer Immunotherapy
Neoantigens Enable Personalized Cancer Immunotherapy
Stephen P. Schoenberger and Ezra Cohen | Apr 1, 2017
Tumors’ mutations can encode the seeds of their own destruction, in the form of immunogenic peptides recognized by T cells.
Infographic: Targeting Cancer Antigens
Infographic: Targeting Cancer Antigens
Stephen P. Schoenberger and Ezra Cohen | Mar 31, 2017
Neoantigens may serve as valuable targets for new immunotherapies.
AACR Q&A: Elaine Mardis
AACR Q&A: Elaine Mardis
The Scientist Staff | Apr 18, 2016
The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.
Napster Cofounder Launches Cancer Initiative
Napster Cofounder Launches Cancer Initiative
Bob Grant | Apr 13, 2016
Billionaire Silicon Valley entrepreneur Sean Parker donates $250 million to unite the cancer research community around the common goal of developing new immunotherapies.
Microbes Meet Cancer
Microbes Meet Cancer
Kate Yandell | Apr 1, 2016
Understanding cancer’s relationship with the human microbiome could transform immune-modulating therapies.
Cancer Be Damned
Cancer Be Damned
Bob Grant | Apr 1, 2016
Teenager Lauren Bendesky turned her cancer diagnosis on its head, using herself as a research subject to test potential therapies.
Immune Influence
Immune Influence
Kate Yandell | Mar 31, 2016
In recent years, research has demonstrated that microbes living in and on the mammalian body can affect cancer risk, as well as responses to cancer treatment.
Mutations Not Tied to Metastasis
Mutations Not Tied to Metastasis
Kerry Grens | Feb 25, 2016
Clinical cases link immune changes to a cancer’s spread through the body, but find no role for so-called “driver” mutations.
CAR-T Therapies Get $1 Billion Boost
CAR-T Therapies Get $1 Billion Boost
Bob Grant | Jul 1, 2015
The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.
Brrrr-ying the Results
Brrrr-ying the Results
Bob Grant | Jul 1, 2015
Holding laboratory mice at temperatures lower than those the animals prefer could be altering their physiology and skewing experimental results.
Search and Destroy
Search and Destroy
Mary Beth Aberlin | Apr 1, 2014
Turning a patient’s immune cells into cancer-fighting weapons
Huge Investment for Cancer Research
Huge Investment for Cancer Research
Kerry Grens | Jan 7, 2014
Six institutions will split a $540 million donation to study cancer immunotherapy among other things.  
Gregory Sonnenberg: Cellular Spy
Gregory Sonnenberg: Cellular Spy
Dan Cossins | May 1, 2013
Research Associate, Perelman School of Medicine, University of Pennsylvania. Age: 27